Design Therapeutics (DSGN) Stock Research

Design Therapeutics

· DSGN

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

786.651 M

-2.63%

Today

Design Therapeutics initiated with bullish view at Wells Fargo, here's why

DSGN

5:31 AM

Over a week ago

Design Therapeutics management to meet with Oppenheimer

DSGN

Sep 3, 2:34 PM

Design Therapeutics reports Q2 EPS (32c), consensus (34c)

DSGN

Aug 3, 8:15 AM

Citizens biotech analysts hold an analyst/industry conference call

Jul 2, 3:32 PM

Design Therapeutics initiates patient dosing in DT-818 trial

DSGN

Jun 30, 8:18 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

What You Missed On Wall Street On Monday

+34

May 18, 4:11 PM

Midday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp

+28

May 18, 12:00 PM

Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial

DSGN

May 18, 7:21 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Design Therapeutics initiated with bullish view at Cantor Fitzgerald, here's why

DSGN

May 12, 7:10 AM

Design Therapeutics initiated with bullish view at Cantor Fitzgerald, here's why

DSGN

May 12, 6:20 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

Design Therapeutics price target raised by $3 at Oppenheimer, here's why

DSGN

May 4, 7:48 AM

Design Therapeutics price target raised by $8 at Piper Sandler, here's why

DSGN

Apr 29, 8:52 AM

Design Therapeutics reports Q1 EPS (29c), consensus (33c)

DSGN

Apr 28, 4:05 PM

Design Therapeutics management to meet with Oppenheimer

DSGN

Apr 21, 4:55 AM

Charts

Today

Design Therapeutics initiated with bullish view at Wells Fargo, here's why

DSGN

5:31 AM

Over a week ago

Design Therapeutics management to meet with Oppenheimer

DSGN

Sep 3, 2:34 PM

Design Therapeutics reports Q2 EPS (32c), consensus (34c)

DSGN

Aug 3, 8:15 AM

Citizens biotech analysts hold an analyst/industry conference call

Jul 2, 3:32 PM

Design Therapeutics initiates patient dosing in DT-818 trial

DSGN

Jun 30, 8:18 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

What You Missed On Wall Street On Monday

+34

May 18, 4:11 PM

Midday Fly By: Dominion to combine with NextEra, Publicis to acquire LiveRamp

+28

May 18, 12:00 PM

Design Therapeutics announces biomarker, clinical data from RESTORE-FA trial

DSGN

May 18, 7:21 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Design Therapeutics initiated with bullish view at Cantor Fitzgerald, here's why

DSGN

May 12, 7:10 AM

Design Therapeutics initiated with bullish view at Cantor Fitzgerald, here's why

DSGN

May 12, 6:20 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

Design Therapeutics price target raised by $3 at Oppenheimer, here's why

DSGN

May 4, 7:48 AM

Design Therapeutics price target raised by $8 at Piper Sandler, here's why

DSGN

Apr 29, 8:52 AM

Design Therapeutics reports Q1 EPS (29c), consensus (33c)

DSGN

Apr 28, 4:05 PM

Design Therapeutics management to meet with Oppenheimer

DSGN

Apr 21, 4:55 AM

Company News

Charts